SCHEMBL1395205

SCHEMBL1395205

CC(ON)(C(=O)c1ccccc1)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 2/20 0.53
MAPT P10636 3/20 0.46
KMT2A Q03164 1/20 0.46
SRC P12931 1/20 0.44
TDP1 Q9NUW8 3/20 0.42
TSHR P16473 3/20 0.42
ALDH1A1 P00352 3/20 0.42
HSD17B10 Q99714 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
CYP2C19 P33261 2/20 0.40
KCNN4 O15554 1/20 0.40
HIF1A Q16665 1/20 0.40
TNF P01375 1/20 0.40
KLF5 Q13887 1/20 0.40
NOD1 Q9Y239 1/20 0.40
ALOX15 P16050 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3128240 0.86 MAPT (0.50) CES1MAPTKMT2ATDP1TSHR
SCHEMBL1999101 0.85 CES1 (0.56) CES1MAPTKMT2ASRCTDP1
SCHEMBL11746305 0.83 CES1 (0.55) CES1MAPTKMT2ASRCTDP1
SCHEMBL1487886 0.83 CES1 (0.65) CES1MAPTKMT2ASRCTDP1
SCHEMBL5140431 0.81 CES1 (0.53) CES1MAPTKMT2ASRCTDP1
Water SCHEMBL8542684 0.81 CES1 (0.62) CES1MAPTKMT2ASRCTDP1
SCHEMBL2842170 0.81 CES1 (0.53) CES1MAPTKMT2ASRCTDP1
SCHEMBL632178 0.80 CES1 (0.51) CES1MAPTKMT2ASRCTDP1
SCHEMBL13148475 0.79 CES1 (0.50) CES1MAPTKMT2ASRCTDP1
SCHEMBL160513 0.79 CES1 (0.50) CES1MAPTKMT2ASRCTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111957073-B Affinity chromatography filler for purifying urokinase, preparation method and application 武汉人福药业有限责任公司 2021-12-24 CN claimed
CN-111957073-A Affinity chromatography filler for purifying urokinase, preparation method and application 武汉人福药业有限责任公司 2020-11-20 CN claimed
EP-3055033-A1 IMPROVED ANTIPERSPIRANT COMPOSITION Riemann Trading ApS (DK) 2016-08-17 EP claimed
WO-2015051805-A1 IMPROVED ANTIPERSPIRANT COMPOSITION RIEMANN TRADING APS (DK) 2015-04-16 WO claimed
EP-0788314-B1 NONDIGESTIBLE FAT COMPOSITIONS CONTAINING DIVERSELY ESTERIFIED POLYOL POLYESTERS FOR PASSIVE OIL LOSS CONTROL PROCTER & GAMBLE (US) 2001-09-12 EP claimed
EP-0788314-A1 NONDIGESTIBLE FAT COMPOSITIONS CONTAINING DIVERSELY ESTERIFIED POLYOL POLYESTERS FOR PASSIVE OIL LOSS CONTROL THE PROCTER & GAMBLE COMPANY (US) 1997-08-13 EP claimed
US-5480667-A CONTAING NONDIGESTIBLE SOLID POLYOL ESTERS OF SPECIFIED CARBON CHAIN LENGTH FATTY ACID DISPERSED IN LIQUID NONDIGESTIBLE OIL; POTATO CHIPS CORRIGAN PATRICK J (US) 1996-01-02 US claimed
WO-1994009639-A1 NONDIGESTIBLE FAT COMPOSITIONS CONTAINING DIVERSELY ESTERIFIED POLYOL POLYESTERS FOR PASSIVE OIL LOSS CONTROL THE PROCTER & GAMBLE COMPANY (US) 1994-05-11 WO claimed
US-5143718-A Aluminum Chloride, Aluminum Salt of Organic Acid RIEMANN TRADING APS (DK) 1992-09-01 US claimed
US-11807904-B2 FRET-labeled compounds and uses therefor PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) 2023-11-07 US disclosed
WO-2023137366-A2 DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES UNIVERSITY OF WASHINGTON (US) 2023-07-20 WO disclosed
CN-115772196-A Compound with plasmin inhibitory activity, preparation method and application thereof 赛诺哈勃药业(成都)有限公司 2023-03-10 CN disclosed
CN-112574145-B Furanone amino acid compound, preparation method thereof and application of furanone amino acid compound as blood coagulation medicine 华南师范大学 2022-08-30 CN disclosed
CN-112557547-B Method for determining in vivo behavior of aminomethylbenzoic acid lyophilized preparation 山东北大高科华泰制药有限公司 2022-08-02 CN disclosed
EP-0692982-A1 RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-01-24 EP disclosed
EP-0386018-B1 ANTIPERSPIRANT COMPOSITION RIEMANN TRADING APS (DK) 1993-03-10 EP disclosed
US-5143718-A Aluminum Chloride, Aluminum Salt of Organic Acid RIEMANN TRADING APS (DK) 1992-09-01 US disclosed
EP-0386018-A1 ANTIPERSPIRANT COMPOSITION. RIEMANN TRADING APS (DK) 1990-09-12 EP disclosed
US-4861887-A CHEMICAL INTERMEDIATE FOR O-CARBOXYL IMIDAZOLINONE AMERICAN CYANAMID COMPANY (US) 1989-08-29 US disclosed
WO-1989002264-A1 ANTIPERSPIRANT COMPOSITION CLAUS RIEMANN & CO. APS (DK) 1989-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11807904-B2 FRET-labeled compounds and uses therefor METTL16, BCDIN3D, GARS1 CES1 3428/4885MAPT 4095/4885KMT2A 2189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.